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Abstract A series of new compounds with quinazolin-4-one structure, synthesized by the 
Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of 
Medicine and Pharmacy “Carol Davila” Bucharest, was studied. Five of them were 
selected, conventionally named S1, S2, S3, S4, S5, and investigated in terms of their 
potential influence on the central nervous system (CNS). For this purpose, the 
antidepressant effect was determined using the forced swimming test; the anxiolytic/ 
anxiogenic effect was determined using the suspended plus-shaped maze (Ugo Basile); 
the effect on the motor activity was determined using the Ugo Basile activity cage; and 
the potential analgesic effect was investigated using the hot plate test (Ugo Basile). 
Compounds S3 and S5 lowered the motor activity and showed an anxiolytic effect, while 
S1 and S2 proved to have antidepressant and analgesic effects.   
A good correlation between antidepressant and analgesic effects was observed, 
consistent with the fact that analgesic drugs, by increasing norepinephrine and serotonin 
levels in the pain inhibiting descendent pathways, can be used as co-analgesics in 
therapy. 
Keywords  quinazolin-4-one derivatives, antidepressant, anxiolytic, analgesic, pharmacological 
research 
Highlights  S1 and S2 reduced the immobilization time in the forced swimming test by 25.98%, 
respectively 28.45% 
 S3 and S5 have been shown to have relatively similar pharmacological profiles with 
respect to influence on HMA and VMA 
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Introduction 
Quinazolone derivatives have been studied in 
preclinical and clinical trials for many and various 
therapeutic purposes: antidepressant (1), anticonvulsant 
(2), analgesic (3), antineoplastic (4), antihypertensive (5), 
or tuberculostatic (6). Moreover, there are several 
approved drugs which belong to the carbamate ester 
derivatives class, many of them with cholinergic actions: 
physostigmine, neostigmine, or rivastigmine.  
The new compound series, synthesized in the 
Pharmaceutical Chemistry Laboratory of the Faculty of 
Pharmacy within UMF “Carol Davila” Bucharest, brought 
together the 4(3H)-quinazolinone structure and carbamic 
ester group (7). 
Table 1. Chemical structure of S1- S5 compounds 
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S1 
C NH NH2
O
 
2-(2-Methyl-4-
oxochinazolin-3(4H)-yl)-
acetohydrazide 
S2 
 
1-[(2-Methyl-4-
oxochinazolin-3(4H)-yl)-
methyl]-3-(3-
bromophenyl)-urea  
S3 
 
2-[2-(2-Methyl-4-
oxochinazolin-3(4H)-yl)-
acetyl]-hydrazino-N-(4-
methoxyphenyl)-
carbothioamide 
S4 
 
2-Methyl-3-[(5-phenyl-
amino)-1,3,4-thiadiazole-
2-yl)-methyl]-chinazolin-
4(3H)-on 
S5 
 
2-Methyl-3-[(N-(3,5-
dimethoxyphenyl)-
carbonyl-oxy)-
carbamoyl-methyl]-
chinazolin-4(3H)-on 
This synthesis resembles other similar processes that 
are part of the recent research directions of the Discipline 
of Pharmaceutical Chemistry, with the purpose of 
obtaining new chemical compounds with potential 
pharmacological actions (8-13).  
In this paper, we present the results of the preclinical 
research performed on these five new compounds in order 
to assess the potential pharmacological actions on the 
central nervous system. We followed all the existing 
protocols of the Laboratory of Pharmacology, the Faculty 
of Pharmacy, UMF “Carol Davila” Bucharest. We 
investigated the antidepressant effect using the forced 
swimming test, the anxiolytic/ anxiogenic effect using the 
suspended plus-shaped maze (Ugo Basile), the effect on 
the motor activity with the Ugo Basile activity cage, and 
the potential analgesic effect using the hot plate test, Ugo 
Basile (14). 
Materials and Methods 
A sample consisting of 94 white males, NMRI mice 
having reached maturity and weighing 25 ± 2.8 g, were 
supplied by the rodent farm of the University of Medicine 
and Pharmacy “Carol Davila”. Animals were quarantined 
for 3 days, and afterward, housed in ventilated cages with 
free access to food and water. Temperature and relative 
humidity were kept constant (22-24oC, 45-60%). 
All experimental procedures were carried out in 
accordance with the Directive 2010/63/UE of September 
22nd, 2010, regarding the protection of animals used for 
experimental and other scientific purposes. All 
experimental procedures were approved by the Ethical 
Committee of the Faculty of Pharmacy Bucharest. The 
experiment was conducted in June 2014. 
For the purpose of selecting the proper animals for the 
proposed pharmacological tests, 94 mice were subjected 
to the Ugo Basile activity cage test and divided into 
groups based on their horizontal motor activity, measured 
every 5 minutes. After exclusion of animals with extreme 
responses, 84 mice remained and were divided into 7 
groups, each containing 12 individuals in such a manner 
that the average responses and the standard deviations 
were as similar as possible. Animals were then allowed 
one day for acclimation within their new groups. On the 
day of the experiment, each group was brought to the lab, 
one hour before the beginning of the experiment, to allow 
them to adapt to the new environment where they were 
kept without food. 
The compounds were administered as shown below: 
• Group I (control) – distilled water 0.1 ml/10g orally  
• Group II (reference) – amitriptyline 10 mg/kg bw susp. 
0.1% orally 
• Group III – S1 100 mg/kg bw, susp. 1% orally 
• Group IV – S2 100 mg/kg bw, susp. 1% orally  
• Group V – S3 100 mg/kg bw, susp. 1% orally  
• Group VI – S4 100 mg/kg bw, susp. 1% orally 
• Group VII – S5 100 mg/kg bw, susp. 1% orally 
One hour after treatment, the mice were subjected to 
the activity cage test to determine their motor activity and 
then to the forced swimming test, in order to determine 
the potential antidepressant effect of the new compounds. 
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One week after the first set of tests (considered 
enough time for the compounds to have been purged from 
the system), all groups received the same treatment again 
and were subjected first to the suspended cross-maze test 
in order to determine the levels of anxiety, and then to the 
hot plate test, in order to evaluate the potential analgesic 
effects of the researched compounds. 
All tests were conducted in accordance with the 
following protocol: in the testing chamber, animals were 
kept in artificial light, without food. Each individual was 
administered the treatment with a 7-minute delay from the 
previous one (5 minutes for the test itself and 2 minutes to 
clean the device before testing the next animal) so that all 
could be tested after the same time interval from the 
moment of receiving the treatment. 
The determination of the motor activity to assess the 
effect on the central nervous system by recording the 
horizontal and vertical movements of mice in the Activity 
Cage Ugo Basile was performed by placing a mouse in a 
corner of the device and monitoring its movements for 5 
minutes. 
The determination of the immobility time of mice in 
forced swimming test (FST) was accomplished by placing 
each mouse in a glass cylinder (25 cm height, 30 cm 
diameter) containing a 20 cm high column of water at a 
temperature of 22 ± 1oC and recording during a 4-minute 
interval after a prior 2-minute interval for adaptation (15). 
The determination of curiosity used the suspended 
cross-shaped maze and involved placing the mouse in the 
center of the device and measuring the time spent in the 
open arms compared to the time spent in the enclosed 
arms during a 5-minute interval. 
The evaluation of pain sensitivity was performed using 
the hot-plate test which consists of placing the mouse on a 
metal plate heated to a 53oC temperature and measuring 
the latency to the mouse’s reaction of licking its forepaws 
or of trying to escalate the Plexiglas walls of the plate. 
Statistical analysis 
Statistical analysis used the software GraphPad Prism 5. 
Comparison between groups used the Student t test (for 
normal distribution) whereas comparison across multiple 
groups used ANOVA. When significant, the Bonferroni 
posttest adjustment was performed for posthoc 
comparisons. The normality of the response distribution 
in collectivity was tested with the D’Agostino & Pearson 
test. 
Results and Discussions 
Group forming 
The 84 mice remaining after excluding 10 individuals 
with extreme responses were divided in 7 homogenous 
groups, each containing 12 individuals. Their baseline 
motor activity is shown below.  
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All of the newly synthesized quinasolines reduced 
the motor activity. S5 had the most intense effect, 
inducing a 29.08% reduction in HMA and a 37.78% 
reduction in VMA compared to the control group, which 
were statistically significant.  
S3 also had an intense effect, but the reduction of the 
motor activity in this case was not statistically significant. 
Amitriptyline, which was used as the reference substance, 
did not influence significantly the motor activity after the 
acute administration.  
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The forced swimming test was performed after acute 
treatment, with this test giving positive results even after a 
single dose, in the case of classical antidepressant drugs.  
The average immobilization time for each group and 
the effect compared to the control group is shown in the 
following figure. 
As expected initially, Amitriptyline reduced the 
immobilization time by 23.85% compared to controls. 
The result however was not statistically significant, 
probably due to the large within-group variance.  
The antidepressant effect of Amitriptyline is well 
documented in the scientific literature (7, 16). Among the 
tested compounds, the highest reduction in the 
immobilization time was induced by S2, thus indicating 
that it has the most intense antidepressant effect 
(28.45%; p<0.05 – ANOVA + Bonferroni posttest). 
Similarly, S1 reduced the immobilization time by 
25.98%. The other three compounds proved to have no 
significant antidepressant effect after only one 
administration.  
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In the suspended cross-maze test, neither of the 
tested compounds induced statistically significant 
changes. However, S3 resulted in a 44.35% increase in 
the time spent in the open arms, and S5 had a similar 
effect (34.36%). Acknowledging the fact that, under 
the influence of anxiolytic drugs, mice tend to spend 
more time in the open arms than the enclosed ones 
further suggests that S3 and S5 might have such an 
effect. Another parameter that can give information 
regarding the anxiolytic potential of a new substance is 
the number of exits performed by mice outside the 
open arms. The mean, standard deviations, and 
comparison with the control group for this parameter 
are shown below. 
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The results confirm that these 2 compounds (S3 and S5) 
have the highest anxiolytic potential, S3 having increased the 
number of exits by 13.9% compared to the control group, 
while S5 shows a similar and stronger pattern, 18.24%. 
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S1 has the most intense analgesic effect compared to 
the control group (79.03%, p<0.01, ANOVA + 
Bonferroni) and also to the reference group (61.87%, 
p<0.05, ANOVA + Bonferoni). S2 also delayed the first 
pain reaction by 58.76% compared to the control group, 
while S4 delayed by 53.69%. S3 and S5 had negligible 
analgesic effects (17, 18).  
Amitriptyline used as a reference had a low 
analgesic effect after a single dose of 10 mg/kg bw. This 
result is consistent with the other reports (19, 20). 
The scientific literature also mentions the use of 
tricyclic antidepressants as co-analgesics in the treatment 
of some forms of pain (21).  
Conclusions 
The five new quinasolines tested in this study 
induced various changes in the parameters investigated in 
the preclinical tests conducted.  
S3 and S5 proved to have similar pharmacological 
profiles in that while S3 lowered HMA by 20% and VMA 
by 28.01% compared to the control group, S5 had the 
same effect on HMA (29,8%; P<0.01 - ANOVA + 
Bonferroni) and to VMA, which was lowered by 37.78% 
compared to the control group.  
The same 2 compounds showed the most intense 
anxiolytic potential by increasing the time spent in the 
open arms of the cross-maze (S3: 44.35%; S5: 34.36%) 
on one hand, and, on the other hand, the number of exits 
from the open arms (S3: 13.9%; S5: 18.24%). However, 
S3 and S5 had no antidepressant or analgesic effect. 
S1 and S2 reduced the immobilization time in the 
forced swimming test by 25.98% and 28.45% respectively 
(p<0.05%; ANOVA + Bonferroni). The same 2 
compounds also registered the most intense analgesic 
effects compared to the control group (S1: 79.03%, 
p<0.01; S2: 58.76%). S1 had a significant analgesic effect 
also compared to amitriptyline (61.87%, p<0.05%; 
ANOVA + Bonferroni). 
A good correlation between the antidepressant and 
the analgesic effects was observed, which is consistent 
with the fact that analgesic drugs, by increasing the 
norepinephrine and serotonin levels in the pain inhibiting 
descendent pathways, can be used as co-analgesics in 
therapy. 
From our analyses, we confirm that the tested 
compounds have high pharmacological potential worthy 
of further investigation. 
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